American Heart Association - You’re the Cure

LoginLogin with Facebook

Remember me Forgot Password

Be the Cure, Join Today!

  • Learn about heart-health issues
  • Meet other likeminded advocates
  • Take action and be heard

Oregon Lobby Day is February 28!

by Grace H. on Tuesday, February 5, 2013

Oregon Lobby Day is February 28, and it will be here before we know it. It is important that we have a strong turnout of volunteers on that day. Sharing your story of how heart disease and stroke has touched your life will help lawmakers to see firsthand how important it is to support policies like tobacco prevention, heart defect screening, and CPR training.   

Having family connections to heart disease is my reason for advocating for the American Heart Association. It gives me joy to know that I am helping to make a difference through advocating and raising awareness about heart disease and stroke.

As a volunteer advocate leader, one of my jobs is to help recruit friends and family to join me for Oregon Lobby Day. You can help too!

  • If you have not signed-up on the “You’re the Cure” network, please do so here. Then can sign up for Lobby Day, read and learn about important topics that will be discussed on Lobby Day; and then share those topics with friends though social media. You can also share your personal story of how heart disease has touched your life and get to know your lawmakers.
  • Facebook is an excellent tool for telling people about Lobby Day and introducing friends and family to the “You’re the Cure” network. I recently created an event on FB to tell people about Lobby Day and encourage them to RSVP for Oregon Lobby Day on the “You’re the Cure” site.

Most Americans have been touched in some way by heart disease and stroke. As the number-one and number-four killers, it is important that we work together and advocate for the American Heart Association. Together we will save more lives.

I hope to see you at Oregon Lobby Day on February 28! Please RSVP here.  

- Guest Blogger Christine Wooley

Leave a Comment

Comments (0)

  • Be the first to respond!

[+] Comments